Back

Effects of diagnosis-to-ablation time and antiarrhythmic drug responsiveness on the rhythm outcomes of atrial fibrillation catheter ablation

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation: treatment 7 - ablation Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Hong-Ju Kim

Dongkang Medical Center, Ulsan (Korea (Republic of))

7 More presentations in this session

Presentation thumbnail
J-curved phenomenon between the prevalence of left atrial low-voltage areas and body mass index existed in patients with atrial fibrillation ablation
Doctor Y. Matsuda (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Impact of age on atrial arrhythmia recurrence following cryoballoon pulmonary-vein isolation
Doctor A. Boehmer (Wiesbaden, DE)
Abstract Slides Video
Presentation thumbnail
Atrial fibrillation cryoablation guided by pulmonary vein pressure: comparison with the standard strategy
Doctor S. Madero (Valladolid, ES)
Abstract Slides Video
Presentation thumbnail
Prevalence of non pulmonary vein triggers and pulmonary pressure change in atrial fibrillation ablation for cardiac amyloidosis patients
Doctor V. La Fazia (Austin, US)
Abstract Slides Video
Presentation thumbnail
Real-world multicenter registry on a novel focal lattice tip catheter toggling between pulsed electric field and radiofrequency for atrial tachyarrhythmia ablation
Doctor D. Della Rocca (Brussels, BE)
Abstract

Access the full session

Session thumbnail
Atrial fibrillation: treatment 7 - ablation

The Event

Event poster

EHRA 2024

7 April - 9 April 2024
You may be interested in
thumbnail
Congress Presentation
Relevance of the diagnosis-to-intervention time on recurrence rates after atrial fibrillation ablation
thumbnail
Congress Presentation
Strategic timing- early and delayed catheter ablation in atrial fibrillation
thumbnail
Congress Presentation
Impact of early intervention with catheter ablation on long-term outcome and disease progression in patients with paroxysmal AF: a single-center analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources